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Coagulation physiology
The integrity of the circulation is maintained through the 
provision of a rapid, potent, but tightly localised coagulation 
response to vascular damage. There is, however, one 
extraordinary problem in the regulation of haemostasis – blood 
flows. Normal haemostasis is the ability of the haemostatic 
system to control activation of clot formation and clot lysis 
in order to prevent haemorrhage without causing thrombosis. 
It classically involves vasoconstriction, platelet adhesion and 
aggregation at the site of injury, leading to a plug formation. 
This is followed by fibrin formation consolidating the plug 
and rendering it stable. All of this occurs without clotting 
occurring elsewhere. Procoagulant products, whether clotting 
factors or platelets, must therefore be spatially localised to the 
site of damage, and/or kinetically controlled so that they are 
inactive when distant from the damaged vessel. 
   The blood coagulation cascade is usually initiated when sub-
endothelial tissue factor is exposed/expressed to the blood flow 
following either damage or activation of the endothelium.1-3 
As a result, the haemostatic mechanism is invoked through 
a complex series of regulated events, involving interactions 
of blood components and tissue proteins, resulting in a 
spectrum from haemorrhage, through controlled haemostasis, 
to thrombosis (Fig. 1).
   A major insight into the functioning of the process of 
coagulation is that the tissue factor/factor VIIa complex of the 
classic ‘extrinsic pathway’ not only activates factor X of the 
‘common pathway’ but also directly activates factor IX4,5 of 
the classic ‘intrinsic pathway’, making factor XII redundant. 
The entire response of clot formation has been characterised 
as a cascade or waterfall of enzymatic reactions, which result 
in a-thrombin converting soluble plasma fibrinogen to the 
insoluble fibrin polymer,6,7 making the coagulation process a 
series of reactions in which the sequentially derived products 
have the capacity to amplify small stimuli to result in the 
rapid generation of large amounts of a-thrombin.8 Tissue 
factor, factor Xa and thrombin are pivotal, together with 
physiological controls (positive and negative feedback loops, 
and natural anticoagulants) that first enhance thrombin 
generation but then preserve vessel patency by limiting 
haemostatic plug formation to areas of injury. Abnormalities 
in these mechanisms can increase thrombosis risk.9
The classic pathways of blood coagulation
The ‘extrinsic pathway’ is the primary route of thrombin 
formation, through which the physiological haemostatic 
response occurs. It occurs through contact with a non-blood 
protein source. The physiological initiator of coagulation 
is tissue factor, which comes into contact with the blood at 
the site of vascular injury and combines with plasma serine 
protease, factor VII.10,11 Being a trans-membrane protein, it is 
ipso facto localised.12 The tissue factor/factor VIIa (TF/VIIa) 
complex activates factor X to factor Xa. It can, however, also 
activate factor IX to IXa.4,5
   Tissue factor, the intrinsic membrane protein, is present 
on the surface of many cell types that are not normally in 
contact with the circulation (Fig. 2). However, it is exposed 
to blood when vascular damage occurs. Vascular damage 
will therefore lead to increasing levels of tissue factor at the 
site of injury. In association with the serine protease factor 
VIIa,13 it initiates the blood coagulation cascade, requiring 
no calcium.10-12 The direct factor IX activation, while slower, 
forms exponentially increasing amounts of thrombin. Tissue 
factor is not released into the circulation in a soluble form 
during normal haemostasis. If there is a major injury there 
is a potential for it to be swept into the circulation, which 
may lead to disseminated intravascular coagulation (DIC).14 
However, at the site of damage platelets interact with 
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exposed/expressed to the blood flow following either the damage or activation of the
endothelium
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of regulated events, involving interactions of blood components and tissue proteins, resulting
in a spectrum from haemorrhage, through controlled haemostasis, to thrombosis. (Figure 1)
Figure 1. The Coagulation Cascade
A major insight into the functioning of the process of coagulation is that the Tissue
Factor/Factor VIIa complex of the classic “Extrinsic Pathway” not only activates Factor X of
the “Common Pathway”, but also directly activates Factor IX
4,5
of the classic “Intrinsic
Pathway”, making Factor XII redundant. The entire response of clot formation has been
characterised as a cascade or waterfall of enzymatic reactions, which result in !-thrombin
Fig. 1. The coagulation cascade.
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, making the coagulation
process a series of reactions in which the sequentially derived products have the capacity to
amplify small stimuli to result in the rapid generation of large amounts of !-thrombin
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. Tissue
factor, factor Xa, and thrombin are pivotal; together with physiological controls (positive and
negative feedback loops, and natural anticoagulants) that first enhance thrombin generation
but then preserve vessel patency by limiting haemostatic plug formation to areas of injury.
Abnormalities in these mechanisms can increase thrombosis risk
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THE CLASSIC PATHWAYS OF BLOOD COAGULATION
The “extrinsic pathway” is the primary route of thrombin formation, through which the
physiological haemostatic response occurs. It occurs through contact with a non-blood protein
source. The physiological initiator of coagulation is tissue factor, which comes into contact
with the blood at the site of vascular injury and combines with plasma serine protease, factor
VII
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Figure 2. The Coagulation Cascade – Initiation Phase
Tissue factor, the intrinsic membrane protein, is present on the surface of many cell types that
are not normally in contact with the circulation. (Figure 2) However, it is exposed to blood
when vascular damage occurs. Thus, vascular damage will lead to increasing levels of tissue
factor at the site of injury. In association with the serine protease factor VIIa
13
, it initiates the
blood coagulation cascade, requiring no calcium
10-12
. The direct factor IX activation, while
slower, forms exponentially increasing amounts of thrombin. Tissue factor is not released into
the circulation in a soluble form during normal haemostasis. If there is a major injury, there is
a potential for it to be swept into the circulation, which may lead to disseminated intravascular
coagulation (DIC)
14
. However, at the site of damage, platelets interact with components of the
Fig. 2. The coagulation cascade – initiation phase.
pg 22-37.indd   22 3/6/06   10:19:31 Am
pg 22-37.indd   23 3/6/06   10:19:32 Am
SAJS
24   VOL 44, NO. 1, FEBRUARY 2006   SAJS
components of the vessel wall at the same time that plasma 
factor VII comes into contact with tissue factor. The platelet 
plug thus prevents the unchecked release of the TF/VIIa 
complex.
   The limited amounts of the serine protease factor Xa 
produced generate minute concentrations of thrombin, which 
partially activates platelets and cleaves the pro-cofactors 
factor V and factor VIII, generating the active cofactors factor 
Va and factor VIIIa, respectively.15,16 The extrinsic pathway 
catalyst is therefore responsible for factor X activation through 
both pathways.17,18 Furthermore, the efficiency of factor X 
activation by the factor VIIIa/IXa complex is significantly 
greater than the efficiency of the TF/VIIa complex. It is 
relevant that the factor IX-dependent route, in contrast to the 
direct activation of factor X by TF/VIIa, involves two enzyme-
catalysed reactions in sequence and therefore provides extra 
amplification over the direct activation of factor X, but will 
take longer.19 The reactions occur on the platelet surface, but 
only on those platelets that are activated and involved at the 
site of vascular injury (see below); the response is therefore 
localised to the site of vascular damage. Multiple control 
mechanisms guard against procoagulant materials entering 
the general circulation and causing disseminated intravascular 
coagulation.20 Obviously, since the latter condition exists, 
these safeguards can on occasion be overrun.
   The pathway classically referred to as the ‘intrinsic pathway’ 
starts with the formation of factor XIIa.21 This can cleave 
prekallikrein to provide kallikrein,22 which in turn reciprocally 
activates factor XII.23 Factor XIIa, in the presence of high-
molecular-weight kininogen, converts factor XI to factor XIa, 
which in turn converts factor IX to factor IXa.24 Factor IXa 
binds with its cofactor protein factor VIIIa, in the presence of 
calcium and the appropriate membrane surface, and activates 
factor X to factor Xa.25 
   Factor VIIIa forms the intrinsic factor Xase complex with the 
serine protease, factor IXa, on a membrane surface provided 
by platelets, microparticles and endothelial and other cells26 
and activates factor X at a 50 - 100-fold higher rate than 
the factor VIIa-tissue factor complex,4 in turn creating a 
‘thrombin burst’ that activates fibrin (Fig. 3).
   Factor VIII circulates in association with von Willebrand 
factor in blood and is released from von Willebrand factor 
during activation of the factor VIII molecule by thrombin 
(Fig. 4). Factor Xa binds to its cofactor protein factor Va, 
in the presence of calcium and the appropriate membrane 
surface, and activates factor II (prothrombin) to IIa (a-
thrombin).27 
   The two soluble plasma proteins, factor V and factor VIII, 
participate in the formation of vitamin K-dependent protein 
complexes. Once formed they are unstable in solution, being 
inactivated by protein C.
   The conversion of prothrombin to a-thrombin (or ‘common 
pathway’) is accomplished via a catalytic subunit, factor Xa in 
the presence of calcium ions, and a regulatory subunit, factor 
Va.28,29 Human factor X circulates in plasma and is converted 
to its active form, factor Xa, by both of the mechanisms 
above.
   Factor V circulates in the blood, both in platelets (~20%) 
and as the soluble plasma protein (~80%). Since a deficiency 
of platelet factor V is associated with decreased factor Xa 
binding and a bleeding diathesis,30 it is clear that the platelet 
pool of this protein plays a major physiological role. The 
factor Xa/Va complex activates prothrombin on an anionic 
phospholipid membrane, the platelet surface. 
   Thrombin generation is the central biochemical reaction 
in both normal haemostasis and thrombosis. The thrombin 
produced further amplifies its own generation through other 
important coagulation events such as activating factor XI31 
and completing platelet aggregation,32 plus factor V and 
VIII activation.15 It also causes the transformation of soluble 
fibrinogen into insoluble fibrin,33,34 and the activation of factor 
XIII to factor XIIIa,35 which stabilises the blood clot.36,37 
Thrombin also participates in damping of its own production 
by complexing with thrombomodulin,38 which is released by 
endothelial cells. These also participate in the activation of 
proteins C and S, which result in the inactivation of factors 
Va and VIIIa.39 Residual serine proteases are inhibited by 
antithrombin III.40-45
   At initiation of coagulation thrombin is generated at a 
relatively low rate, with partial activation of platelets and 
proteolysis of factor V, factor VIII, factor VIIa, factor IXa, 
factor Xa, and factor XIa are also generated.15,16,46
   Subsequently, in the presence of all procoagulant proteins 
at their mean plasma concentrations, the propagation phase 
of thrombin generation occurs, with the clot occurring at 
the inception of this phase. The characteristic features of 
the propagation phase are a prothrombin conversion at a 
high rate, completion of platelet activation, and solid clot 
formation15,16,37,46,47 (Fig. 5).
Platelets 
Platelets form the platelet plug, playing a pivotal role in 
haemostasis with platelet membrane glycoproteins mediating 
binding to subendothelial tissue and aggregation into 
vessel wall at the same time that plasma factor VII comes into contact with tissue factor. The
platelet plug thus prevents the unchecked release of the TF/VIIa complex.
The limited amounts of the serine protease factor Xa produced generate minute
concentrations of thrombin, which partially activates platelets and cleaves the pr -cofactors
factor V and factor VIII generating the active cofactors--factor Va and factor VIIIa,
respectively
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. Thus the extrinsic pathway catalyst is responsible for factor X activation
through both pathways
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. Furthermore, the efficiency of factor X activation by the factor
VIIIa/IXa compl x is significantly g ater th n the efficiency of the TF/VIIa complex. It is
relevant that the factor IX-dependent route, in contrast to the direct activation of factor X by
TF/VIIa, involves two enzyme-catalysed reactions in sequence and therefore provides extra
amplification over the direct activation of factor X, but will take longer
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of vascular injury (see below), thus the response is localised to the site of vascular damage.
Multiple control mechanisms guard against procoagulant materials entering the general
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The pathway classically referred to as the “Intrinsic Pathway” starts with the f rmation of
factor XIIa
21
, which can cleave prekallikrein to provide kallikrein
22
, which in turn reciprocally
activates factor XII
23
. Factor XIIa, in the presence of high-molecular-weight kininogen,
onverts factor XI to factor XI , which in tur converts factor IX to f ctor IXa
24
. Factor IXa
binds with its cofactor protein factor VIIIa, in the presence of calcium and the appropriate
membrane surface, and activates factor X to factor Xa
25
.
Factor VIIIa forms the intrinsic factor Xase complex with the serine protease, factor IXa, on a
membrane surface provided by platelets, microparticles, and endothelial and other cells
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activates factor X t a 50-100-fold higher rate than the factor VIIa- issue factor complex
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turn creating a “thrombin burst” that activates fibrin. (Figure 3)
Fig. 3. The coagulation cascade – propagation phase.
Figure 3. The Coagulation Cascade – Propagation Phase
Factor VIII circulates in association with von Willebrand factor in blood and is released from
von Willebrand factor during activation of the factor VIII molecule by thrombin (Figure 4).
Factor Xa binds to its cofactor protein factor Va, in the presence of calcium and the
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Figure 4. Factor VIII:von Willebrand Factor
The two soluble plasma proteins, factor V and factor VIII, participate in the formation of
vitamin K-dep ndent protein complexes. Once formed, they are unstable in solution, being
inactiv ted by protein C.
The conversion of prothrombin to !-thrombin (or “Co mon Pathway“) is accomplished via a
catalytic subunit, factor Xa in the presence of calcium ions, and a regulatory subunit, factor
Va
28,29
. Human factor X circulates in plasma, and is converted to its active form, factor Xa, by
both of the mechanism above.
Factor V circulates in the blood, both in platelet (~20%), and as the soluble plasma protein
(~80%). Since a deficiency of platelet factor V is associated with decreased factor Xa binding
and a bleeding diathesis
30
, it is clear that the platelet pool of this protein plays a major
physiological role. The factor Xa/Va complex activates prothrombin on an anionic
phospholipid membrane: the plat let surface.
Thrombin generation is the central bi chemical reactio in both normal haemostasis and
thrombosis. The thrombin produced further amplifies its own generation through other
important coagulation events like activating factor XI
31
, completing platelet aggregation
32
, plus
fa tor V and VIII activation
15
. It also causes the transformation of soluble fibrinogen into
insoluble fibrin
33,34
, and the activation of factor XIII to factor XIIIa
35
, which stabilises the blood
clot
36,37
. Thrombin also participates in damping of its own production by complexing with
thrombomodulin,
38
which is released by endothelial cells. These also participate in the
activation of proteins C and S, which result in the inactivation of factors Va and VIIIa
39
.
Residual serine proteases are inhibited by antithrombin III
40-45
.
Fig. 4. Factor VIII: von Willebrand factor.
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haemostatic plugs.48 Reduced platelet activity will result in 
a bleeding tendency, while stimulation of platelets can lead 
to thrombosis.49 In addition, aggregated, activated platelets 
provide procoagulant phospholipid-equivalent surfaces 
upon which the complex-dependent reactions of the blood 
coagulation cascade are localised.50,51
   Platelets are small (2 µm diameter), non-nucleated blood 
cells, which are activated rapidly after blood vessel injury or 
blood exposure to artificial surfaces, providing haemostasis 
by four interconnected mechanisms: (i) adhering to sites of 
vascular injury or artificial surfaces; (ii) releasing compounds 
from their granules; (iii) aggregating together to form a 
haemostatic platelet plug; and (iv) providing a procoagulant 
surface for activated coagulation protein complexes on their 
phospholipid membranes.52
   The adhesion to the subendothelium is the initial step 
in platelet activation,53 which is extremely rapid and is 
facilitated by von Willebrand factor binding to platelet surface 
glycoprotein Ib/IX/V.54-56 Platelets can also adhere to vascular 
wall associated fibrin or fibrinogen through interaction with 
platelet surface glycoprotein IIb/IIIa.57,58 After adhering to 
the subendothelium, platelets undergo activation leading to a 
shape change with development of pseudopods. Intracellular 
signalling processes lead to increased cytoplasmic calcium and 
initiation of a secretory release reaction, whereby products are 
released into the surrounding milieu.59 Platelets also have 
numerous intrinsic glycoproteins embedded in the outer 
surface of their plasma membrane that are receptors for 
agonists, such as adrenaline, thrombin, collagen, and platelet-
activating factor, which can initiate platelet aggregation60 
(Fig. 6). 
   As mentioned above, activated platelets also play a vital 
procoagulant role, linking platelet function and coagulation 
activation. Platelet membrane phospholipids undergo a 
rearrangement during activation, providing a binding site for 
phospholipid-dependent coagulation complexes that activate 
both factor X and prothrombin,61 accelerating coagulation 
through the assembly of multi-enzyme complexes with great 
catalytic efficiency. The platelet surface membrane also 
interacts with factors Xa and Va to form the prothrombinase 
complex, as well as promoting the assembly of the factor 
IXa-VIIIa complex required for factor Xa activation.62 These 
interactions should not be overlooked, since they dramatically 
enhance enzymatic formation of both thrombin and factor 
Xa63 and in the absence of membrane the formation of the 
complex is either abolished or impaired.64,65 Calcium is also an 
essential component for efficient complex formation.66
Fibrin formation
Activated a-thrombin rapidly converts soluble plasma 
fibrinogen to an insoluble fibrin polymer by limited proteolysis, 
thus consolidating the haemostatic platelet plug. Fibrinogen is 
synthesised in the liver and is present in plasma and platelet 
a-granules. It is an acute-phase reactant: with maximal 
stimulation, fibrinogen synthesis can be increased 20-fold. 
Thrombin also activates the plasma transglutaminase, factor 
XIII,67 which covalently cross-links the fibrin polymers both 
longitudinally and transversely.68 Calcium enhances lateral 




The alternative route of activation of factor XI via thrombin69 
is a positive feedback system, which explains both the 
requirement for factor XI and the lack of a requirement for 
factor XII. A reasonable scenario is therefore that tissue factor 
initiates coagulation, leading to fast thrombin production. 
Thrombin then feeds back, producing small amounts of 
factor XIa. The XIa in itself may then have a positive feedback 
on itself, thus leading to an increase in the rate of factor XI 
activation. When the initiation phase of thrombin generation 
is prolonged, either because of low tissue factor concentration 
or inhibitory effects of elevated concentrations of some 
proteins involved in blood coagulation, factor XI plays an 
important role.47
Factor IX activation by TF/VIIa
Although factor XIa is an activator of factor IX in one of the 
simplest reactions of coagulation, requiring only calcium as 
a cofactor, as discussed above, the factor VIIa-tissue factor 
complex activates factor IX as well as activating factor X.4,5,70 
This links the extrinsic pathway directly into the intrinsic 
one.
Factor VIII activation by thrombin and  
factor Xa
Factor VIII circulates as a complex with von Willebrand 
factor, and normally exists in an almost inactive state, 
requiring activation to factor VIIIa. Activation is due to the 
feedback action of either factor Xa or thrombin. Upon factor 
VIII activation by thrombin or factor Xa, it is released from 
von Willebrand factor, which enables binding of the activated 
cofactor.
At initiation of coagulation thrombin is generated at a relatively low rate, with partial activation
of platelets and proteolysis of factor V, factor VIII, factor VIIa, factor IXa, factor Xa, and factor
XIa are also generated
15,16,46
.
Figure 5. The Coagulation Cascade – Thrombin amplification
Subsequently, in the presence of all procoagulant proteins at their m an plasma
concentrations, the propag tion phase of thrombin generation occurs, with the clot
occurring at the inception of this phase. The characteristic features of the propagation





Platelets form the platelet plug, pl ying a pivotal role in haemostasis with platelet membrane
glycoproteins mediati g binding to subendothelial tissue and aggregati n into haemostatic
plugs
48
. Reduced pl telet activity will result in a bleedi tendency, while stimulation of
platelets can lead to thrombosis
49
. In addition, aggregated, activated platelets provide
procoagulant phospholipid-equivalent surfaces upon which the complex-dependent reactions
of the blood coagulation cascade are localised
50,51
.
Platelets are small (2-µm-diameter), non-nucleated blood cells, which are activated rapidly
after blood vessel injury or blood exposure to artificial surfaces, providing haemostasis by 4
interconnected mechanisms: (1) adhering to sites of vascular injury or artificial surfaces, (2)
releasing compounds from their granules, (3) aggregating together to form a haemostatic
platelet plug, and (4) providing a procoagulant surface for activated coagulation protein
complexes on their phospholipid membra es
52
.
Fig. 5. The coagulation cascade – thrombin amplification.
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Figure 6. The Coagulation Cascade – The Platelet Plug
The adhesion to the subendothelium is the initial step in platelet activation
53
, which is
extremely rapid and is facilitated by vWF binding to platelet surface glycoprotein Ib/IX/V
54-56
.
Platelets can also adhere to vascular wall associated fibrin or fibrinogen through interaction
with platelet surface glycoprotein IIb/IIIa
57,58
. After adhering to the subendothelium, platelets
undergo activation leading to a shape change with development of pseudopods. Intracellular
signalling processes lead to increased cytoplasmic calcium and initiation of a secretory
release reaction, whereby products are released into the surrounding milieu
59
. Platelets also
have numerous intrinsic glycoproteins embedded in the outer surface of their plasma
membrane that are receptors for agonists, such as adrenaline, thrombin, collagen, and
platelet-activating factor, which can initiate platelet aggregation
60
(Figure 6).
As mentioned above, activated platelets also play a vital procoagulant role, linking platelet
function and coagulation activation. Platelet membrane phospholipids undergo a
rearrangement during activation, providing a binding site for phospholipid-dependent
coagulation complexes that activate both factor X and prothrombin
61
, accelerating coagulation
through the assembly of multi-enzyme complexes with great catalytic efficiency. The platelet
surface membrane also interacts with factors Xa and Va to form the prothrombinase complex,
as well as promoting the assembly of the factor IXa-VIIIa complex required for factor Xa
activation
62
. These interactions should not be overlooked, since they dramatically enhance
enzymatic formation of both thrombin and factor Xa
63
and in the absence of membrane the
formation of the complex is either abolished or impaired
64,65
. Calcium is also an essential












Fig. 6. The coagulation cascade – the platelet plug.
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Positive feedbacks
The positive feedbacks in coagulation play a major role in the 
architecture of the system:  there are several feedback loops. 
In a positive feedback an enzyme formed later in the pathway 
acts to provide something that accelerates its own formation. 
Thrombin/factor Xa
The known major feedback loops of clotting, all originating 
via either factor Xa or thrombin, result in the formation of 
both enzymes and activated cofactors. The production of 
thrombin is therefore rapid (≤ 1 minute) and self-reinforcing 
because of its feedback activation of numerous coagulation 
proteins (factor V, VIII, XI and VII)31,41,71,72 that contribute 
to thrombin production. This provides the threshold above 
which the ‘thrombin burst’ occurs.
Platelet activation
Platelets have numerous receptors for ligands ranging from 
fibrinogen, collagen, thrombin and thrombospondin to von 
Willebrand factor and fibronectin.60 Of note is that most of 
the platelet activators exert their action by binding to specific 
receptors on the platelet surface membrane. A possible 
exception to this is activation by thrombin, one of the 
most potent platelet activators known.63 Minor quantities of 
thrombin formed early in haemostasis, prior to coagulation,73 
bind to platelet receptors to elicit release and aggregation. 
Platelet aggregation itself also involves positive feedbacks 
through the release from platelets of platelet agonists such as 
adenosine diphosphate (ADP) and thromboxane A2.
Factor VII activation
The major activator of factor VII is factor Xa, which generates 
factor VIIa. Although anionic phospholipid alone does support 
this reaction, it is much faster in the presence of tissue factor. 
Tissue factor therefore has two distinct cofactor roles in 
coagulation:  enhancing the activity of factor VIIa on factors 
IX and X, and accelerating the feedback activation of factor 
VII by factor Xa.  Factor VII can also be feedback-activated, 
but at lower rates, by the TF/VIIa complex and by thrombin 
and factor IXa.74
Cofactor activation
Both major plasma cofactors, factors VIII and V, are activated in 
feedback loops.  The principal activator of both is thrombin,75 
but both are also activated by factor Xa in the presence of 
anionic phospholipid.76,77 Factor VIII activation by factor Xa 
constitutes a feedback, but activation of factor V does not. 
It is possible that factor Xa action plays a significant role in 
the early phases of coagulation before significant thrombin 
generation.
Positive feedbacks in the presence of  
inhibitors  
The enzymes catalysing positive feedbacks, thrombin and 
factor Xa, are also the major targets of plasma inhibitors, 
chiefly antithrombin III (ATIII).  Inhibition may therefore 
be expected to play a role in the regulation of the feedbacks. 
Positive feedback loops, when subject to control by inhibitors 
such as ATIII, confer threshold properties on the system.78 
Below the threshold no response will occur, while above the 
threshold the response should be at or near maximum.
Negative feedbacks
Control of coagulation reactions
Several natural anticoagulant mechanisms are present, able 
to exert damping effects upon each step of the coagulation 
cascade.79 Two types of inhibition exist in the regulation 
of thrombin production. The first depends on the plasma 
concentration of ample activated inhibitors, the major 
example being ATIII,80 which is able to effectively neutralise 
all serine proteases produced during the blood coagulation 
process.44 Possibly a2-macroglobulin is another minor player. 
In addition to this, protein C anticoagulant mechanisms will 
regulate activated cofactors.81 However, antithrombin III does 
appear to be the most quantitatively important.  
   The second type of inhibition, which is so far unique, is the 
tissue factor pathway inhibitor (TFPI), involving a negative 
feedback in which an inhibitory species is formed only when 
the system is activated. It can bind and inactivate both factor 
Xa and factor VIIa simultaneously.45  TFPI is also an impor- 
tant regulator of the serine proteases, its principal targets 
being factor Xa and the factor VIIa-TF/factor Xa complex.40
   The dynamic inhibitory system is generated when thrombin 
binds to its cofactor thrombomodulin and activates protein 
C.38 Activated protein C attenuates the coagulation reaction 
of factor V/Va and factor VIII/VIIIa.41,43 
   The protein C system and antithrombin III have prominent 
effects on the propagation phase of thrombin generation.82,83 
In the presence of both, TFPI and antithrombin III, the 
concentration of factor Xa (the limiting reactant of thrombin 
generation) is decreased. Additionally, antithrombin III also 
inhibits other serine proteases produced in situ during the 
reaction44 (see Fig. 1). As a consequence of synergistic effects, 
thrombin generation becomes a threshold-limited process, 
influenced by relatively small changes in the concentrations 
of procoagulants and their inhibitors.74
   Therefore, a number of plasma proteins are able to inhibit 
serine proteases involved in coagulation, fibrinolysis, and 
kinin formation. These include ATIII, heparin cofactor II, a2-
macroglobulin, a1-antitrypsin, tissue factor pathway inhibitor, 
protein C inhibitor, a2-antiplasmin, and plasminogen 
activator inhibitor-1 (PAI-1). The similarity in structure and 
mechanism of action of these proteins (with the exception of 
a2-macroglobulin) has led to the general term serpins for these 
serine protease inhibitors:84
   Antithrombin III, which is also known as antithrombin 
or heparin cofactor I, inhibits its target enzymes by forming 
1:1 enzyme:inhibitor complexes in which the active site of 
the enzyme is blocked.85 Factors IXa, Xa, XIa and XIIa are 
inactivated by ATIII in a manner similar to that outlined 
for thrombin.86-88 Although the interaction is reversible,89 
dissociation is probably too slow to be significant. Since the 
plasma ATIII concentration is in significant excess of the sum 
of the concentrations of all the coagulants, there is ample mass 
of ATIII available. However, despite the level being adequate 
in mass terms, the second-order kinetics of its action mean 
that the rates of inhibition of target enzymes are a function of 
its concentration, both in pure systems and plasma.90-92 
   Heparin cofactor II (HCII) is a serine protease inhibitor 
(serpin) that is synthesised by the liver and circulates in 
plasma.  About 40% of the protein equilibrates with an 
pg 22-37.indd   26 3/6/06   10:19:53 Am
pg 22-37.indd   27 3/6/06   10:19:53 Am
SAJS
28   VOL 44, NO. 1, FEBRUARY 2006   SAJS
extravascular compartment and it has been detected in the 
intima of normal human arteries. It inhibits thrombin, but 
has no activity against other proteases involved in coagulation 
or fibrinolysis.93
 a2-Macroglobulin can inhibit numerous serine proteases, 
including thrombin, factor Xa, plasmin and kallikrein, albeit 
at a relatively modest rate compared with other inhibitors.81
 Tissue factor pathway inhibitor is a serum component 
that has been shown to form a quaternary complex with 
factor Xa, factor VIIa and tissue factor in the presence of 
calcium and thereby suppresses the activity of the extrinsic 
cascade.94,95
 Protein C. A blood coagulation inhibitor, autoprothrombin 
IIa, is generated when thrombin is converted to prothrombin. 
The vitamin K-dependent protein, which was termed protein 
C, was subsequently found to be the same protein as 
autoprothrombin IIa.96 
 Plasminogen activator inhibitor-1 plays the major 
physiological part in suppressing the function of tissue 
plasminogen activator as well as urokinase, thus preventing 
the activation of the fibrinolytic pathway.  In contrast to most 
other serine protease inhibitors in plasma, the normal level of 
PAI-1 is quite low. PAI-1 can also inhibit other coagulation 
system proteases including plasmin, activated protein C and 
thrombin.97,98
Monitoring of coagulation abnormalities  
Normal haemostasis is the ability of the haemostatic system 
to control activation of clot formation and clot lysis in order 
to prevent haemorrhage without causing thrombosis. All this 
occurs with no clotting elsewhere. This basic definition of 
normal haemostasis, depending on several finely balanced 
mechanisms, shows that:
 1. There are three systems involved simultaneously in 
haemostasis: the formation of clots, involving platelets and 
the coagulation pathways; this is opposed by the anticoagulant 
system, and thirdly, the fibrinolysis of clots once they have 
been formed.
 2. The absence or presence of haemorrhage or thrombosis 
depends on a delicate balance between the activated 
procoagulants and anticoagulant systems, while the clot 
maturity, or early breakdown once formed, will depend on the 
fibrinolytic system. In other words, an excess of activated pro-
coagulants will primarily result in thrombosis. On the other 
hand, an increased anticoagulant potential (antithrombin, 
protein C, etc.), or decrease in activation of procoagulant 
factors will result in haemorrhage. In addition, enhanced 
fibrinolysis will also lead to bleeding.
 3. Given the intricate interactions between the three 
systems, any instrument measuring coagulation endpoints may 
only be able to identify single points, rather than the interaction 
between systems. This is because coagulation is a dynamic 
process dependent on the interaction of an array of factors 
rather than one determined by actual values of individual 
agents. 
 As the understanding of the normal mechanisms of 
coagulation grows, so does the ability to monitor haemostasis, 
becoming more specific and accurate as instrumentation 
techniques become simpler and more efficient, facilitating 
the monitoring of haemostasis in the clinical setting.99 The 
haemostatic process of coagulation is extremely complex, 
with multiple interactions between factors, including the 
coagulation and fibrinolytic proteins, platelets, activators and 
inhibitors. This is in order to avoid uncontrolled action in 
either direction, and is accomplished by numerous positive 
and negative inhibiting and activating feedback mechanisms. 
As a result, the actual quantity or level of an individual 
factor does not necessarily reflect its functional status. 
With this complicated and interactive dynamic system, the 
measurement of static endpoints will not reflect the dynamics 
of the system. 
   Any medical coagulopathy, as opposed to a surgical bleed, 
needs the actual underlying cause determined in order to 
direct the therapy appropriately. Traditionally, haematological 
tests like the prothrombin time (PT) and its derived value, 
the international normalised ratio (INR), activated partial 
thromboplastin time (aPTT), bleeding time and activated 
clotting time (ACT) (see below) have been done. However, 
while they are useful endpoint markers to identify the lack of 
a given factor, they do not measure the dynamic interaction 
between the different systems, as blood coagulation occurs 
efficiently on cell surfaces such as activated platelets, 
monocytes, and fibroblasts. Both PT and aPTT are highly 
artificial in vitro systems with major limitations.100
Standard tests of coagulation  
Most of the routine tests of coagulation are performed 
on blood that has had the coagulation cascade suspended 
through the addition of sodium citrate 3.8%, which removes 
the calcium from the blood. The sample is then spun down 
leaving only plasma, with almost no platelets. In order to 
measure the various tests of coagulation endpoints, calcium is 
added in abundance, as are the various factors used to initiate 
coagulation. As a result, these tests are generally useful for 
measuring absolute values, or endpoints. However, they will 
not measure the interaction between pro- and anticoagulant 
factors, because of the addition of excess initiating factors.
Prothrombin time (PT/INR)101
This test measures the overall efficiency of the extrinsic system. 
It was introduced as an assay of prothrombin in plasma before 
many of the factors participating in the coagulation reactions 
were identified. It is now used as a screening tool of the 
activities of fibrinogen, prothrombin and factors V,  VII, and 
X. It is also used to monitor the oral anticoagulants, since 
these lower the levels of prothrombin, VII and X (Fig. 7).
 The test is initiated by recalcifying citrated plasma in the 
presence of thromboplastin. Thromboplastin is added far in 
excess of normal levels and is a source of tissue factor in a 
the interaction between pro- and anticoagulant factors, because of the addition of excess
initiating factors.
Prothrombin time (PT / INR)101
This test measures the overall efficiency of the extrinsic system. It was introduced as an
assay of prothrombin in plasma before many of the factors participating in the coagulation
reactions were identified. It is now used as a screening tool of the activities of fibrinogen,
prothrombin and factors V, VII, and X. It is also used to monitor the oral anticoagulants, since
these lower the levels of prothrombin, VII and X (Figure 7).
The test is initiated by recalcifying citrated plasma in the presence of thromboplastin.
Thromboplastin is added far in excess of normal levels and is a source of tissue factor in a
suspension of phospholipids. The time that elapses until the plasma clots is the PT and is
predominantly determined by: i) factor VIIa/tissue factor in the presence of phospholipids and
calcium activating factor X; ii) factor Xa/Va in the presence of phospholipids and calcium
























Figure 7. The Prothrombin Time
The test has to be standardised and consists of taking blood in a ratio of 9 parts blood to 1
part 3.8% citrated blood. Inter-assay variability is increased by the variability of methods used
to detect clot formation.
In order to interpret this, the prothrombin time ratio (PTR) needs to be calculated, i.e. the
patient’s result compared with the mean reference range. It then needs to be corrected for the
slope of response of the assay to oral anti-coagulants. This is the international sensitivity
index (ISI). The International Normalised Ratio (INR) is then calculated as INR = PTR
ISI
. “INR
shorter than the reference range are uncommon and have not been consistently correlated
with any clinical situation.” Calculation of the INR improves standardisation, but is still limited
Fig. 7. The prothrombin time.
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suspension of phospholipids. The time that elapses until the 
plasma clots is the PT and is predominantly determined by: (i) 
factor VIIa/tissue factor in the presence of phospholipids and 
calcium activating factor X; (ii) factor Xa/Va in the presence 
of phospholipids and calcium activating prothrombin; (iii) 
thrombin cleaving fibrinogen; and (iv) fibrin monomers 
polymerising. 
   The test has to be standardised and consists of taking blood 
in a ratio of 9 parts blood to 1 part 3.8% citrated blood. Inter-
assay variability is increased by the variability of methods used 
to detect clot formation.
  In order to interpret this, the prothrombin time ratio (PTR) 
needs to be calculated, i.e. the patient’s result compared with 
the mean reference range. It then needs to be corrected for 
the slope of response of the assay to oral anticoagulants. This 
is the international sensitivity index (ISI). The INR is then 
calculated as INR = PTRISI. INRs shorter than the reference 
range are uncommon and have not been consistently correlated 
with any clinical situation. Calculation of the INR improves 
standardisation, but is still limited by variations in reagents 
and methods. As a measure of anticoagulation, the INR only 
has meaning for patients on a stable dose of anticoagulants; it 
therefore cannot be used in patients who have not been taking 
their anticoagulants for at least a week or in patients who have 
abnormal PTs for reasons such as liver disease. However, in 
practice the INR is used to test for intrinsic liver function in 
hepatitis, as factor VII is produced in the liver.
   The ACL 200 analyser simultaneously determines the 
PT and fibrinogen using the PT-fibrinogen recombinant (PT-
FIB) reagent. The normal INR range is 1.0 to 1.3.
Activated partial thromboplastin time102,103
This is usually used as a screening test to identify acquired 
or inherited deficiencies or inhibitors of factors VIII, IX, and 
XI. Reduced activation of fibrinogen, prothrombin, or factors 
V and X can prolong the aPTT. It is also used to monitor 
heparin therapy (Fig. 8). 
   Again the test is initiated with citrated platelet-poor 
plasma being incubated and recalcified after the addition 
of a source of platelets or platelet substitute together with a 
contact activator and phospholipid to ‘activate’ coagulation. 
The time that elapses until the plasma clots is the aPTT. 
While the normal has been difficult to establish as there is 
great variability, hence the ‘controlled activation’ of citrated 
blood to give an endpoint, it is again important to note that 
the variability of coagulation results from subtle changes 
occurring in the dynamic coagulation system and that these 
are lost in the aPTT.
   The aPTT is sensitive to heparin and is usually used 
to monitor anticoagulant therapy. It is noted that some 
patients with disseminated intravascular disease (DIC) or 
malignancies may have a shortened aPTT reflecting the in 
vivo state; however, a shortened aPTT or PT rarely point to 
significant findings of enhanced coagulation. 
   The ACL 200 analyser determines the activated partial 
thromboplastin time using the APTT reagent and calcium, 
giving the printout aPTT result in seconds, with the normal 
range being 26 to 40 seconds.
Red blood cell count (RBC)/platelet count104
Using fresh EDTA anticoagulated blood, both red blood cell 
and platelet counts are analysed by a single optical cytometer 
after appropriate dilution of the blood sample with ADVIA 120 
RBC/PLT reagent. The red blood cells are isovolumetrically 
sphered and lightly fixed with glutaraldehyde to preserve the 
spherical shape. Red cells and platelets are counted from 
the signals from a common detector with two different gain 
settings, with the platelet signals being amplified considerably 
more than the RBC signals. The haemoglobin concentration 
is calculated from the RBC count and the MCV.
   The test is performed on the ADVIA® 120.
Bleeding time (BT)105
This is a screening test for inherited or acquired disorders 
of platelet function and for von Willebrand’s disease. It 
is measured as the time required for a standardised skin 
wound to stop bleeding. It is thought to be determined 
by the rate of platelet plug formation. It should only be 
performed by experienced operators and each centre should 
have its own reference range (~2.5 - 10 minutes). A lower 
platelet count can prolong the bleeding time and it may 
be affected by multiple other factors. It is not possible to 
reliably demonstrate abnormal bleeding in anyone with an 
acquired platelet dysfunction. The test has a poor sensitivity 
and specificity. The major conclusions of a position article on 
bleeding time are: (i) in the absence of a history of a bleeding 
disorder, the bleeding time is not a useful predictor of the 
risk of haemorrhage associated with surgical procedures; (ii) 
a normal bleeding time does not exclude the possibility of 
excessive haemorrhage associated with invasive procedures; 
and (iii) the bleeding time cannot be used to reliably identify 
patients who may have recently ingested aspirin or non-
steroidal anti-inflammatory agents.106
Activated clotting time107
This is mostly used to monitor heparin anticoagulation. The 
result is available within minutes of starting the test, and it is 
therefore often used in a clinical situation. It is conceptually 
similar to the aPTT, except that fresh whole blood is tested 
rather than citrated plasma. Whole blood is added into a tube 
containing an activator, and the time that elapses until clot 
is formed is the ACT. This assay therefore depends on the 
same reactions as the aPTT plus the effects of platelets and 
any other cells that can influence coagulation. In this regard 
it reflects in vivo conditions much better. However, it only 
measures an endpoint and does not identify where the source 
of a coagulation abnormality rests.
by variations in reagents and methods. As a measure of anticoagulation, the INR only has
meaning for patients on a stable dose of anticoagulants; therefore this cannot be used in
patients who have not been taking their anti-coagulants for at least a week or in patients who
have abnormal prothrombin times for reasons such as liver disease. However, in practice, the
INR is used to test for intrinsic liver function in hepatitis, as factor VII is produced in the liver.
The ACL 200 analyser simultaneously determines the prothrombin time and fibrinogen usi g
the PT-Fibrinogen Recombinant (PT-FIB) reagent. The normal INR range is: 1,0 to 1,3.
Activated partial thromboplastin time (aPTT)102,103
This is usually used as a screening test to identify acquired or inherited deficiencies or
inhibitors of factors VIII, IX, and XI. Reduced activation of fibrinogen, prothrombin, or factors V
























Figure 8. The activated Partial Thromboplastin Time (aPTT)
Again the test is initiated with citrated platelet-poor plasma being incubated and recalcified
after the addition of a source of platelets or platelet substitute together with a contact activator
and phospholipid to “activate” coagulation. The time that elapses until the plasma clots is the
aPTT. While the normal has been difficult to establish as there is great variability, and hence
the “controlled activation” of citrated blood to give an endpoint, it is again important to note
that the variability of coagulation results from subtle changes occurring in the dynamic
coagulation system and that these are lost in the aPTT.
The aPTT is sensitive to heparin and is usually used to monitor anticoagulant therapy. It is
noted that some patients with disseminated intravascular disease (DIC) or malignancies may
have a shortened aPTT reflecting the in vivo state, however, a shortened aPTT or PT rarely
point to significant findings of enhanced coagulation.
Fig. 8. The activated partial thromboplastin time (aPTT).
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Platelet aggregation108 
Platelet-rich plasma (PRP) is stirred and a suspension of 
collagen is added to it. As a result some of the platelets adhere 
to the collagen coating the fibres. After the adherence has 
occurred, the free platelets begin to swell and stick together, 
with the reaction accelerating until large platelet masses 
have formed. This is the process of platelet aggregation; it is 
distinct from the adherence to collagen although initiated 
by it. Platelet aggregation occurs when aggregation agents 
are added to PRP, which is continually being stirred. As 
aggregation proceeds, platelet clumping occurs. In the plasma, 
this reduces the optical density of the PRP allowing more light 
(infra red) to pass through. If all the platelets clumped, the 
resultant optical density would be equivalent to that of the 
platelet-poor plasma (PPP). The light transmittance through 
the PPP represents 100% and that of the PRP 0% aggregation. 
The aggregometer develops a voltage proportional to the 
transmittance of light through the plasma. This voltage is 
recorded on a strip chart recorder as a function of time. Since 
the optical channel is automated, a voltage representing the 
difference in transmittance between the PRP and PPP cuvettes 
is automatically developed and this voltage is registered on the 
strip chart recorder.
 Tests on the whole blood aggregometer optical channel 
detect platelet aggregation in a 0.45 ml sample of PRP by 
measuring infrared light transmission through the sample. 
 Calculations. Provided that the recorder is run long 
enough to permit a plateau or a reversal of the responses to 
occur, a plot of the maximum aggregation achieved during the 
time verses the logarithm of the agonist concentration gives a 
characteristic sigmoidal curve.
 Normal range.  The platelets of normal subjects usually 
produce a single reversible primary wave with 1 µmol/l ADP 
or less, a biphasic aggregation with 2.5 µmol/l, and a single 
irreversible wave at 5 - 10 µmol/l. A single-phase response is 
observed after a lag phase lasting not more than 1 minute with 
1 and 4 µg/ml of collagen. A single phase or biphasic response 
is seen with 1.2 mg/ml of ristocetin and biphasic aggregation 
is observed with 2 - 10 µmol/l of adrenaline.
   Interpretation of results.  The length of time between 
the addition of the aggregating agent and the onset of the 
recorder’s pen deflection provides a clue as to how the 
aggregation agent works: whether through directly aggregating 
platelets or stimulating the release of ADP. The slope of the 
curve allows estimation of the speed of aggregation while 
the course, maximum height and return to baseline provides 
information on the responsiveness of the platelets, from 
different sources, to the same stimulus.
   ADP. Low concentrations of ADP (0.5 - 2.5 µmol/l) cause 
primary or reversible aggregation. At very low concentrations 
of ADP, platelets may disaggregate after the first phase. In 
the presence of higher concentrations of ADP an irreversible 
secondary wave of aggregation is associated with the release of 
dense and a-granules due to activation of the arachidonic acid 
pathway. Failure to aggregate with ADP is caused by aspirin 
consumption, storage pool disease (no a- or dense granules 
released), or thrombasthenia (due to a missing or defective 
platelet membrane glycoprotein).
 Collagen. The aggregation response to collagen is preceded 
by a short ‘lag’ phase lasting 10 - 60 seconds. The duration 
of the lag phase is inversely proportional to the concentration 
of the collagen used and to the responsiveness of the 
platelets tested. This phase is succeeded by a single wave of 
aggregation due to activation of the arachidonic pathway. 
Higher doses of collagen can cause sudden increase in 
intra-platelet calcium concentration, thus bypassing the 
prostaglandin pathway. The following causes defective or no 
response to collagen aggregating agents: aspirin consumption, 
thrombasthenia thromboxane synthetase deficiency or cyclo-
oxygenase deficiency.
   Ristocetin. Ristocetin reacts with von Willebrand factor 
and the membrane receptor to induce platelets to clump 
together (agglutination). It does not activate any of the three 
aggregation pathways or cause the initial granule release. 
Defective aggregation is caused by a glycoprotein deficiency 
or defect and is associated with disease.
   Adrenaline. No shape change precedes aggregation, but 
the response thereafter resembles the ADP response. Such 
a response is usually obtained with concentrations of 2 - 10 
µmol/ml. Some clinically normal people will fail to aggregate 
with adrenaline.
Antithrombin III (AT III)109
AT III or heparin cofactor I is the major inhibitor of blood 
coagulation, and as such a deficiency is associated with a 
high risk of thromboembolic disorders. It is also essential 
for effective heparin therapy. By inhibiting the coagulation 
proteases, especially thrombin, factors Xa and IXa, AT 
III prevents uncontrolled coagulation and thrombosis. The 
assay is based on a chromogenic substrate and on factor Xa 
inactivation, with the method being consequence specific and 
not influenced by heparin cofactor II.
   Antithrombin levels in patient plasma are measured 
automatically on the ACL Futura in two stages: (i) incubation 
of the plasma with factor Xa reagent in the presence of an 
excess of heparin; and (ii) quantification of the residual factor 
Xa activity with a synthetic chromogenic substrate.
   The paranitroaniline released, monitored at 405 nm, is 
inversely proportional to the antithrombin III level in the test 
sample. The result is reported in percentage activity and is 
automatically calculated, with the method being linear from 
10% to 150%. The normal range is 85 - 120%.
Thrombin-antithrombin complex (TAT)110
This is an enzyme immunoassay for the determination 
of human thrombin/antithrombin III complex. Enzygnost® 
TAT micro is an enzyme immunoassay for the quantitative 
determination of thromblin/antithromblin III complex in 
human plasma and is used for the diagnosis of disturbances 
in blood coagulation, which are associated with changes in 
the activity of the coagulation system. Persons predisposed to 
thrombosis and DIC are found to have elevated concentrations 
of TAT.
D-dimer (XDP)111
D-dimer-containing moieties are formed by plasmin 
degradation of factor XIIIa cross-linked fibrin, with elevated 
levels being found in clinical conditions such as deep-vein 
thrombosis (DVT), pulmonary embolism (PE) and DIC.
   For quantitative analysis using the ACL Futura the degree 
of agglutination is directly proportional to the concentration 
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of D-dimer in the sample and is determined by measuring 
the decrease of the transmitted light at 405 nm caused by the 
aggregates (turbidimetric immunoassay).
   Quantitative test. The QXDP test is used and results are 
reported in ng/ml, with the interpretation of results being 
that agglutination will occur within 180 seconds for samples 
containing more than 250 ng/ml D-dimer. The mean level of 
D-dimer (XDP) in the healthy population is between 8 and 
135 ng/ml and neat plasma from normal healthy individuals 
should not agglutinate.  If no agglutination is observed a 
thrombotic condition is unlikely.  The circulatory half-life of 
D-dimers is about 12 hours and therefore elevated levels can 
persist for some time after the active process has ceased.
Fibrinogen
This is measured using an IL Test™ PT-Fibrinogen 
Recombinant kit.  The test is based on a combined assessment 
of the prothrombin time and fibrinogen level by the addition 
of recombinant rabbit thromboplastin to the plasma.  The 
fibrinogen is quantified by relating the absorbance or light 
scatter during clotting to a calibrator
Catecholamines
Heparinised samples are immediately centrifuged at 4 
000 rpm for 10 minutes, after which plasma is frozen at 
–70°C for batching. Plasma catecholamine concentrations are 
measured by electrochemical detection after separation with 
reverse-phase high-pressure liquid chromatography (using 
dihydrobenzylamine as internal standard). The coefficient of 
variation is 7.9% for noradrenaline and 8.7% for adrenaline; 
the limit of sensitivity is 20 pg/ml.
Whole-blood dynamic tests of coagulation 
There are two tests using whole blood to measure clot 
formation rather than measuring end-points as is done in the 
standard tests.
Sonoclot
Sonoclot (Sonoclot R Coagulation Analyser, Sienco, Inc.) 
analysis provides a simple test of cellular and plasmatic 
coagulation properties.112 It and the thrombelastograph (TEG) 
(see below) assess the coagulation process in whole blood and 
may therefore be physiologically more relevant than assays 
of isolated haemostatic components. Hypercoagulability is 
detected in a high proportion by both techniques, with the 
clotting rates of the Thrombelastograph and Sonoclot being 
significantly correlated.113,114 In addition, Sonoclot coagulation 
analyses correlate better with blood loss than aPTT and 
platelet count in the routine coagulation analyses.115
Thromboelastography (TEG)
The Thrombelastograph Haemostasis Analyser is a non-invasive 
diagnostic instrument designed to analyse the coagulation 
state of a blood sample in order to assess haemostasis 
conditions from haemorrhagic through thrombotic.
TEG design and operating principles
The TEG analyser’s approach to the monitoring of patient 
haemostasis is based on two facts: (i) the end result of the 
haemostasis process is a single product – the clot; and (ii) 
the clot’s physical properties (rate, strength, and stability), 
which will determine whether the patient will have normal 
haemostasis, will haemorrhage or will develop thrombosis.
 The TEG analyser involves two mechanical parts to 
measure the physical properties of the clot, a cup and a pin. 
The special stationary cylindrical cup holds the blood (0.36 
ml) and is oscillated through an angle of 4°45´ at 37°C. 
   Each rotation cycle lasts 10 seconds. The pin is suspended 
in the blood sample by a torsion wire and is monitored for 
motion, which is either transduced mechanically to a heated 
stylus, moving across heat-sensitive graph paper on a chart 
recorder, or in the newer models converted by a mechanical-
electrical transducer to an electrical signal, which can be 
monitored by a computer. When no clot exists, the motion 
of the cuvette does not affect the pin and a straight line is 
recorded. The torque of the rotating cup is only transmitted 
to the immersed pin after fibrin-platelet bonding has linked 
the cup and pin together. The strength of these fibrin-platelet 
bonds affects the magnitude of the pin motion, such that 
strong clots move the pin directly in phase with the cup 
motion. The magnitude of the output is therefore directly 
related to the strength of the formed clot. As the clot retracts 
or lyses, these bonds are broken and the transfer of cup 
motion is diminished.
   The resulting haemostasis profile is a measure of the time 
it takes for the first fibrin strand to be formed, the kinetics 
of clot formation, the strength of the clot and dissolution of 
clot.
TEG assessment
The coagulation profile evaluated by the TEG is a graphic 
method of displaying a measure of the kinetics of clot 
formation and dissolution as well as of clot quality. It 
monitors shear elasticity, a physical property of a blood clot, 
and is therefore sensitive to all the interacting cellular and 
plasmatic components in the blood that affect the rate or 
structure of a clotting sample and its breakdown. 
   The clot’s ability to perform useful mechanical work (the 
work of haemostasis) is a function of the net result of the 
interactive coagulation proteins and cellular elements involved 
in the process of haemostasis. In essence, the TEG analyser 
measures the ability of the clot to perform mechanical work 
throughout its structural development (Fig. 9).  
  A recent advance is computerisation of the TEG, which 
essentially gives greater accuracy and consistency than 
manual measurements by removing the human error from the 
measurements. The TEG pattern is divided into component 
variables. The various parameters of the TEG are explained 
below and reflected in Table I.
   Reaction time.  The time from the start of a sample run 
until the first significant levels of detectable clot formation 
(amplitude = 2 mm in the TEG tracing).  This is the point 
at which most traditional coagulation assays reach their 
end-points. r-time is prolonged by anticoagulants and factor 
deficiencies and shortened by hypercoagulable conditions.
  Achievement of a certain clot firmness. The time from 
the measurement of r (beginning of clot formation) until a 
fixed level of clot firmness is reached (amplitude = 20 mm). 
Therefore, k-time is a measure of the speed or clot kinetics 
to reach a certain level of clot strength. k is shortened by 
increased fibrinogen level and, to a lesser extent, by platelet 
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function, and is prolonged by anticoagulants that affect both.
 The kinetics of clot development.  The a-angle is closely 
related to k-time, since they are both a function of the rate 
of polymerisation.  The angle is more comprehensive than 
k-time, since there are hypocoagulable conditions in which 
the final level of clot firmness does not reach an amplitude 
of 20 mm (in which case k is undefined).  Similar to k, a is 
enlarged by increased fibrinogen levels and, to a lesser extent, 
by platelet function, and is decreased by anticoagulants that 
affect both.
 Maximum amplitude. This is the measurement of 
maximum strength of stiffness (maximum shear modulus) 
of the developed clot. Clot strength is the result of two 
components – the modest contribution of fibrin to clot 
strength and the much more significant contribution of the 
platelets.
   The basic TEG measurements of kinetics, strength and 
stability of a clot can be determined by using a native 
whole blood sample. This has provided a sensitive method 
for monitoring conditions of hyper-, hypo- and normal 
coagulation, and fibrinolysis (Fig. 10). However, by using the 
measurements and established normal ranges and indices, the 
patterns can be quantified as to the degree of abnormality. 
Haemoscope provides reference normal ranges for the TEG 
(Table II).
   The TEG therefore provides a quantitative and qualitative 
indication of the coagulation state of a blood sample by 
measuring coagulation parameter and recording the kinetic 
changes in a sample of whole blood, plasma or platelet 
rich-plasma as it clots, retracts and breaks apart (lysis). 
As a dynamic measurement of coagulation, it reflects the 
interaction between cell surfaces and coagulation factors 
(pro- and anti-) involved in the localisation, amplification and 
modulation of coagulation functions, rather than endpoints. 
   It is a ‘near-patient’ coagulation test that poses many 
theoretical advantages over standard tests, not least of which 
is the yield of information relating to cumulative effects of 
several components of coagulation at a given instant.116,117 
More recently, the contribution of platelets and soluble 
clotting components to clot strength has been the focus of 
clinical studies using TEG,118 for coagulation changes in both 
coagulation factors and platelets.119 It will also determine the 
degree of anticoagulation produced by low-molecular-weight 
heparin, with the r-time from the TEG correlating with serum 
anti-Xa concentration.120 In summary, it can provide rapid 
information on coagulation status and specific treatment 
options within 30 minutes.116 It is the leading point-of-care 
monitor in many instances.121
Comparison of clinical tests
TEG has been widely used in a clinical setting,122 but there 
have been conflicting opinions on its validity as a stand-alone 
test. In an editorial in Anesthesia and Analgesia, Samama 
casts a critical light on TEG.123 He observes that among 
other things, TEG is the leading point-of-care monitor for 
hypercoagulability113,121 and has become so popular that 
many groups consider it a self-sufficient coagulation test. 
However he goes on to state that ‘it is not a conventional 
hemostasis test, thus remaining a second-level test and 
therefore not reaching the standards acceptable of most 
academic hemostasis societies’. He agrees with Whitten124 
‘that if thromboelastography is to be considered a promising 
hemostasis tool, its global management must be improved 
as it deserves a new evaluation leading to a final validation 
TAble I. TeG TRAcInG pARAmeTeRs
r  r-time is the period of time of latency from the time 
that the blood was placed in the TeG analyser until 
the initial fibrin formation
k  k-time is a measure of the speed to reach a certain 
level of clot strength
a  Alpha angle measures the rapidity of fibrin build-up 
and cross-linking (clot strengthening)
mA  maximum amplitude is a direct function of the 
maximum dynamic properties of fibrin and platelet 
bonding via GpIIb/IIIa and represents the ultimate 
strength of the fibrin clot
lY30  lY30 measures the rate of amplitude reduction 30 
minutes after MA and reflects clot stability.
Fig 10. Qualitative Analysis
The basic TEG measurements of kinetics, strength and stability of a clot can be determined
by using a native whole blood sample. This has provided a sensitive method for monitoring
conditions of hyper-, hypo-, normal coagulation, and fibrinolysis (Figure 10). However, by
using the measurements and established normal ranges and indices, the patterns can be
quantified as to the degree of abnormality. Haemoscope provides reference normal ranges for
the TEG (Table 2).
R (min) K (min) !-Angle (deg) MA (mm)
Native 15.5-23.0 5.5-10.5 22.0-38.0 47.0-58.0
Table 2. Standard Parameter Measurement
The TEG therefore provides a quantitative and qualitative indication of the coagulation state
of a blood sample by measuring coagulation parameter and recording the kinetic changes in a
sample of whole blood, plasma or platelet rich-plasma as it clots, retracts, and breaks apart
(lysis). As a dynamic measurement of coagulation, it reflects the interaction between cell
surfaces and coagulation factors (pro- and anti-) involved in the localisation, amplification and
modulation of coagulation functions, rather than endpoints.
It is a 'near patient' coagulation test, which poses many theoretical advantages to standard
tests, not least of which is the yield of information relating to cumulative effects of several
components of coagulation at a given instant
116,117
. More recently, the contribution of platelets
and soluble clotting components to clot strength has been the focus of clinical studies using
thromboelastography
118
, for coagulation changes in both coagulation factors and platelets
119
.
Fig. 10. Qualitative analysis.
TAble II. sTAndARd pARAmeTeR meAsuRemenT 
	 r	(min)	 k	(min)	 a-Angle	(deg.)	 MA	(mm)
native 15.5 - 23.0 5.5 - 10.5 22.0 - 38.0 47.0 - 58.0
Fig. 9. TEG tracing parameters.
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or it will remain an expensive, non-validated point-of-care 
monitor’.123
   Conversely, TEG has been quoted as a proven useful 
research tool and compared with six common tests (the 
haematocrit, platelet count, fibrinogen, PT, aPTT and 
fibrin split products) by Zuckerman.125 The results indicated 
that, although there is a strong relationship between the 
thromboelastographic variables and these common laboratory 
tests, thromboelastographic variables contain additional 
information on the haemostatic process. TEG has been used 
to confirm normal coagulation in the face of an abnormal 
prothrombin time.126 Kang et al.127 found the relationship 
between TEG and standard laboratory tests of coagulation to 
be similar to that of other researchers,125,128 with the greatest 
correlation occurring between r-time and aPTT, while 
McNicol et al.129 found the relationship between standard 
tests of coagulation and TEG to be an inconsistent correlate. 
However, the authors comment that this is not surprising 
given that TEG variables are interdependent, measuring the 
interaction of the coagulation cascade and platelets in whole 
blood rather than specific endpoints in centrifuged plasma 
samples. The dynamic data provided by TEG allow far more 
appropriate replacement therapy.130 
   TEG is a real-time monitor of global haemostasis, enabling 
readily available analysis of coagulation in a shorter period of 
time than laboratory coagulation tests would take under ideal 
circumstances, thus providing useful and prompt identification 
of coagulation disorders.131 It allows rapid intraoperative 
diagnosis and specific management,117 covering the entire 
field of haemostasis in the perioperative setting, from platelet 
function, to fibrinolysis. Davis and Chandler132 found in their 
study that of various assays tested, only abnormal TEG values, 
a-angle (p < 0.01) and k-time (p < 0.04), were associated 
with an increased risk of bleeding. Bleeding times were not 
predictive of an increased risk of post-biopsy bleeding. All 
prothrombin time, partial thromboplastin time and platelet 
count abnormalities were mild and none of these assays 
predicted bleeding. It was concluded that TEG was the best 
assay for detecting mild coagulation abnormalities associated 
with an increased risk of bleeding. 
   With the advent of computerisation in the past decade, 
TEG has evolved from a research laboratory tool into a 
compact processor, providing global information on the entire 
coagulation process. The battery of traditional coagulation 
tests is based on the isolated, static laboratory end-points 
and as a result they do not take into account the interactions 
within the clotting cascade and platelets in whole blood. 
Haemostasis is an integrated, interactive, dynamic, and 
extremely complex process involving coagulation proteins, 
activators, cellular elements and inhibitors, which is recorded 
by TEG,133 while standard tests of coagulation stop measuring 
at the first onset of clot formation – in other words, at static 
endpoints of blood coagulation. This provides no information 
on the dynamics of clot formation, strength and stability. As a 
result, it is difficult to assess what the exact dynamic process 
for inhibition of clotting is.
   In the clinical setting, TEG may be used to rapidly 
assess coagulation abnormalities in the initial assessment 
of coagulation in trauma patients.134 When compared with 
platelet count and PT/aPTT only TEG was predictive of 
early transfusion (p < 0.05), leading to the conclusion that 
TEG is a rapid, simple test that can broadly determine 
coagulation abnormalities. TEG and Sonoclot analysis were 
100% accurate in predicting bleeding after cardiopulmonary 
bypass and significantly better predictors of postoperative 
haemorrhage than routine coagulation tests.135 Essell et al.136 
tested the utility of TEG versus platelet studies (BT, platelet 
count, mean platelet volume) and standard coagulation tests 
(PT, aPTT, fibrinogen). The sensitivities of the BT (71.4%) 
and platelet count (100%) were similar to TEG (71.4%), but 
the specificity (89.3%) of TEG in predicting postoperative 
bleeding was greater than that of the bleeding time (78.5%) 
and platelet count (53.6%), suggesting that patients with 
a normal TEG who have a post-bypass bleed should not 
be given blood products empirically, but that a surgical 
cause should rather be excluded. Kang et al.127 found TEG 
to be a reliable and rapid monitoring system during liver 
transplantation and Martin et al.137 validate the role of  TEG 
during paediatric liver surgery, finding a 100% sensitivity 
(8/8) and 73% specificity (8/11) in predicting increased 
postoperative bleeding. In a study comparing the sensitivity 
of the ACT, aPTT and TEG, the ACT was less sensitive to 
residual heparin anticoagulation than aPTT or TEG.138 In 
addition TEG using heparinase cups to analyse anticoagulated 
blood during cardiac surgery is useful to guide treatment with 
haemostatic components. Twelve-hour chest tube losses were 
not different between groups despite the threefold reduction in 
the use of haemostatic products, showing that intra-operative 
monitoring of coagulation in the anticoagulated patient can 
be used to guide treatment.139  TEG, by providing information 
on the interaction of all the coagulation precursors, gives 
more clinically useful information on coagulation than that 
available from the coagulation profile or the activated clotting 
time alone. TEG was a significantly better predictor (87% 
accuracy) of postoperative haemorrhage and need for re-
operation than was the ACT (30%) or coagulation profile 
(51%),140 with TEG providing diagnostic data within 30 
minutes of blood sampling. TEG is also useful in assessing 
platelet function in the presence of thrombocytopenia141 and 
pre-eclampsia/eclampsia.142
   In screening for hypercoagulability, standard laboratory 
tests that may indicate hypercoagulability include a high 
platelet count, high levels of coagulation factors VII, VIII, IX, 
X and XI, or fibrinogen levels, low levels of protein S, protein 
C, antithrombin, and the presence of a lupus anticoagulant, 
while the TEG indicators of hypercoagulability are a short 
r-time and k-time, a large MA or an a-angle that is large 
and rapidly increasing. This has been noted with increased 
frequency in a variety of patient groups who are considered to 
be at increased risk of thrombosis, with the predictive value of 
the TEG being higher than other systems. Hypercoagulability 
may not be reflected by standard coagulation monitoring 
and may be predominantly influenced by increased platelet 
reactivity,143 which needs to be measured as an dynamic test 
and not as an end-point.
Conclusion
Coagulation is a dynamic and intricate process that becomes 
more complicated to understand as more is discovered about 
the process. On the other hand, the clinical end-point is still 
‘Will the patient clot or not?’ With the many interactions 
taking place concomitantly there is not one simple answer 
to establish the exact state of the coagulation system, but 
the dynamic coagulation tests like the TEG are definitely 
getting closer to providing an understanding. Certainly rapid 
bedside, or theatre, information on coagulation status with 
rapid analysis of appropriate therapy will go far in managing 
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the coagulation status, especially when taken in 
conjunction with the clinical findings.
   Much of this work was based on my Ph.D. thesis 
and a chapter on ‘Fluids and coagulation’ currently 
in press. Some of the diagrams were courtesy of Mike 
James (based on slides from Novo Nordisc) and Eli 
Cohen (Haemoscope).
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